NICE guidance now published
TA211 - Prucalopride for the treatment of chronic constipation in women1
Resolor:
Prucalopride is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes, at the highest tolerate recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered.
If treatment with prucalopride is not effective after 4 weeks, the woman should be re-examined and the benefit of continuing treatment reconsidered.
Prucalopride should only be prescribed by a clinician with experience of treating chronic constipation who has carefully reviewed the woman's previous courses of laxative treatments specified in the first point above.
NICE assessed cost-effectiveness and advised that Resolor is an appropriate use of NHS resources
TA211 Costing Template (from Nice.org.uk) >
References
1. National Institute for Clinical Excellence. TA211 Constipation (women) - Prucalopride guidance. 15 December 2010 (Accessed 16 December 2010).
Please note that Practice Services UK and/or Shire Pharmaceuticals cannot be held responsible for the content of external links.
Resolor:
Prucalopride is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes, at the highest tolerate recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered.
If treatment with prucalopride is not effective after 4 weeks, the woman should be re-examined and the benefit of continuing treatment reconsidered.
Prucalopride should only be prescribed by a clinician with experience of treating chronic constipation who has carefully reviewed the woman's previous courses of laxative treatments specified in the first point above.
NICE assessed cost-effectiveness and advised that Resolor is an appropriate use of NHS resources
TA211 Costing Template (from Nice.org.uk) >
References
1. National Institute for Clinical Excellence. TA211 Constipation (women) - Prucalopride guidance. 15 December 2010 (Accessed 16 December 2010).
Please note that Practice Services UK and/or Shire Pharmaceuticals Ltd cannot be held responsible for the content of external links.
